Citations 2
The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium
Moghadasi, Setareh , Vreeswijk, Maaike P.G. , Janssen, Linda AM, Borg, Åke , Ehrencrona, Hans , Paulsson-Karlsson, Ylva, Wappenschmidt, Barbara , Engel, Christoph , Gehrig, Andrea, Hansen, Thomas van Overeem , Thomassen, Mads , Jensen, Uffe Birk , Kruse, Torben A., Ejlertsen, Bent , Gerdes, Anne‐Marie , Pedersen, Inge Søkilde , Caputo, Sandrine M. , Couch, Fergus J., Hallberg, Emily J., Ouweland, Ans MW van den, Collée, Margriet J., Teugels, Erik , Adank, Muriel A. , Luijt, Rob B. van der , Mensenkamp, Arjen R. , Oosterwijk, Jan C., Blok, Marinus J. , Janin, Nicolas, Claes, Kathleen , Tucker, Kathy , Viassolo, Valeria , Eccles, Diana , Devilee, Peter , Asperen, Christi J. van , Goldgar, David E., Gómez, E. , Meeks, Huong , Janssen, Linda A.M., Arnold, Norbert , Collée, Margriet , Toland, Amanda Ewart , Spurdle, Amanda B. , Eccles, Diana , Vreeswijk, Maaike P G , Claes, Kathleen B M , Ehrencrona, Hans , van der Luijt, Rob B , Engel, Christoph , van Asperen, Christi J , Gómez-García, Encarna B , Hansen, Thomas van Overeem , Devilee, Peter
Journal of Medical Genetics | May 11, 2017 | Volume: 55 | Issue: 1 | Pages: 15-20
Background We previously showed that the BRCA1 variant c.5096G>A p.Arg1699Gln (R1699Q) was associated with an intermediate risk of breast cancer (BC) and ovarian cancer (OC). This study aimed to assess these cancer risks for R1699Q carriers in a larger cohort, including follow-up of previously studied families, to further define cancer risks and to propose adjusted clinical management of female BRCA1*R1699Q carriers. Methods Data were collected from 129 BRCA1*R1699Q families ascertained internationally by ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles) consortium members. A modified segregation analysis was used to calculate BC and OC risks. Relative risks were calculated under both monogenic model and major gene plus polygenic model assumptions. Results In this cohort the cumulative risk of BC and OC by age 70 years was 20% and 6%, respectively. The relative risk for developing cancer was higher when using a model that included the effects of both the R1699Q variant and a residual polygenic component compared with monogenic model (for BC 3.67 vs 2.83, and for OC 6.41 vs 5.83). Conclusion Our results confirm that BRCA1*R1699Q confers an intermediate risk for BC and OC. Breast surveillance for female carriers based on mammogram annually from age 40 is advised. Bilateral salpingo-oophorectomy should be considered based on family history.
Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer
Tang, Jiang-bo, Stopfer, Jill E. , Lilli, Dana R., Hamel, Nancy , Monteiro, Álvaro N.A. , Messick, Troy E. , Powers, Jacquelyn M. , Yonker, Alexandria, Goldgar, David E., Davidson, H. Rosemarie, Nathanson, Katherine L. , Domchek, Susan M. , Tischkowitz, Marc D. , Couch, Fergus J. , Foulkes, William D. , Greenberg, Roger A. , Monteiro, Alvaro N , Nathanson, Katherine L
Cancer Discovery | December 26, 2012 | Volume: 3 | Issue: 4 | Pages: 399-405
Abstract BRCA1 and BRCA2 are the most important breast and ovarian cancer susceptibility genes. Biallelic mutations in BRCA2 can lead to Fanconi anemia and predisposition to cancers, whereas biallelic BRCA1 mutations have not been confirmed, presumably because one wild-type BRCA1 allele is required during embryogenesis. This study describes an individual who was diagnosed with ovarian carcinoma at age 28 and found to have one allele with a deleterious mutation in BRCA1, c.2457delC (p.Asp821Ilefs*25), and a second allele with a variant of unknown significance in BRCA1, c.5207T>C (p.Val1736Ala). Medical records revealed short stature, microcephaly, developmental delay, and significant toxicity from chemotherapy. BRCA1 p.Val1736Ala cosegregated with cancer in multiple families, associated tumors showed loss of wild-type BRCA1, and BRCA1 p.Val1736Ala showed reduced DNA damage localization. These findings represent the first validated example of biallelic deleterious human BRCA1 mutations and have implications for the interpretation of genetic test results. Significance: Accurate assessment of genetic testing data for BRCA1 mutations is essential for clinical monitoring and treatment strategies. Here, we report the first validated example of an individual with biallelic BRCA1 mutations, early-onset ovarian cancer, and clinically significant hypersensitivity to chemotherapy. Cancer Discov; 3(4); 399–405. ©2012 AACR. See related commentary by D'Andrea, p. 376 This article is highlighted in the In This Issue feature, p. 363